Companies: 10,795·Total market cap: $144.5T
Brainstorm Cell Therapeutics Inc.

Brainstorm Cell Therapeutics Inc.

BCLIOTCHealthcare● Active
$0.80
+$0.05(+6.87%)
Market Cap$8827820
P/E Ratio
52W High$1.33
52W Low$0.46

Brainstorm Cell Therapeutics Inc.(BCLI)股价预测与分析师目标价

华尔街共识、12 个月目标价、模型推演与 EPS/营收预期 — 来自分析师数据与历史行情。

bcli · 股价预测 · 3 位分析师(近3月)· FMP · 更新于 2026年6月8日

分析师评级与共识

基于过去 3 个月内 3 位华尔街分析师

SellBuy

Buy

3 位分析师

共识

评级分布

Strong Buy
0
Buy
3
Hold
0
Sell
0
Strong Sell
0
合计: 3 · 买入占比: 100.0%

12 个月目标价

High

$0.00

Consensus

$0.00

+0.0% upside

Low

$0.00

Median: $0 · Last Close: $0.80

Brainstorm Cell Therapeutics Inc.(BCLI)的分析师共识为 Buy,基于过去 3 个月内 3 位华尔街分析师的评级。BCLI 的 12 个月平均目标价为 $0.00,相对当前价 $0.80 代表 +0.0% 的潜在上行空间。

短期股价预测

算法生成 · 每日更新

DatePredicted PriceChange
2026-06-09$0.845.00%

1-day model range: $0.83–$0.85. Peak: $0.85 (+5.00%).

长期股价预测

年度股价预测 · 2027 / 2028 / 2029 / 2030 / 2031

YearAvg PriceChange
2027$0-50.0%
2028$0-62.5%
2029$0-67.2%
2030$0-69.2%
2031-70.2%
Confidence:Medium

基于技术分析的股价预测

14 项技术面信号(SMA×6 + EMA×6 + RSI + MACD)· EEAT 方法论透明

Market Sentiment

BULLISH

Based on 14 technical indicators

86%7%7%
12Buy
1Neutral
1Sell
RSI (14)63.0Neutral
MACDBULLISH

Refreshes daily from EOD close

Moving Averages · BCLI · Jun 8, 2026

Simple Moving Average (SMA)
MA 5$0.78BUY
MA 10$0.74BUY
MA 20$0.72BUY
MA 50$0.77BUY
MA 100$0.72BUY
MA 200$0.69BUY
Current $BCLI · Price above MA = BUY signal
Exponential Moving Average (EMA)
EMA 5$0.77BUY
EMA 10$0.76BUY
EMA 20$0.74BUY
EMA 50$0.74BUY
EMA 100$0.73BUY
EMA 200$0.87SELL
Current $BCLI · Price above MA = BUY signal
How we calculate: Technical sentiment is derived from 14 indicators — SMA(5,10,20,50,100,200), EMA(5,10,20,50,100,200), RSI(14), and MACD(12,26,9) — calculated from historical EOD price data. BUY = current price above MA; SELL = below. 14 TA signals + historical EOD price data · Updated daily. Independent of analyst consensus data. Not investment advice.

最新分析师评级与调整

Filter:
Maxim Group2024-07-11
Upgrade ↑
HoldBuy
Maxim Group2023-09-28
Downgrade ↓
BuyHold
Maxim Group2023-03-31
Maintains
BuyBuy
Maxim Group2021-02-05
Upgrade ↑
HoldBuy
H.C. Wainwright2018-05-15
Maintains
BuyBuy
HC Wainwright & Co.2018-05-15
Maintains
BuyBuy
Maxim Group2017-08-17
Maintains
BuyBuy

Wall Street analysts have recently issued updated ratings on Brainstorm Cell Therapeutics Inc. (BCLI) stock. Of the recent 7 rating actions, 2 were upgrades and 1 were downgrades. 3 analysts currently cover BCLI.

分析师推荐趋势

Buy ratings11
Hold ratings00
Sell ratings00

BCLI analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 1 per month.

财务预测:EPS 与营收一致预期

Revenue This Year

$258M

↓ 42.1% YoY

Revenue Next Year

$427M

↑ 65.5% YoY

EPS This Year

$-1.61

EPS Next Year

$-1.07

↓ 33.5% YoY

EPS ForecastReported vs Estimated

Reported EPSHistorical estimateAnalyst forecast (future)

Analysts forecast BCLI EPS of $-1.61 for the current fiscal year, based on estimates from 1 analysts. The BCLI revenue forecast is $258M for the current year. These are analyst consensus estimates via FMP / S&P Global.

关于预测与目标价

BCLI 股价预测由两类独立数据源支撑:来自 3 位华尔街分析师(S&P Global / FMP)的共识评级,以及基于历史日终价计算的技术分析。BCLI 的共识目标价为 $0.00(+0.0% 上行空间),分析师共识为 Buy。

BCLI 的短期预测(明日)为 $0.84(+5.00%)。 BCLI 对 2027 年的股价预测均值为 $0。 BCLI 对 2030 年的预测区间为 $0–$0。

Brainstorm Cell Therapeutics Inc. 在 OTC 上市,代码 BCLI。BCLI 在 2027 年的整体展望偏积极,在覆盖分析师中约 100% 对应 Buy 共识。

常见问题答案综合分析师目标价、一致预期及页面展示的模型结果。

常见问题

BCLI 预测 · 8 个问题

根据 3 位华尔街分析师,BCLI 的 12 个月平均目标价为 $0.00,最高 $0.00、最低 $0.00。若有图表,中位目标价可在上方查看。相对当前价 $0.80,隐含约 +0.0% 的上行空间。

BCLI 目标价BCLI 分析师目标价BCLI 12个月目标价目标价 BCLI

· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)

⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.